One in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk continues its efforts to promote the use of genuine, FDA approved GLP-1s while combatting the use of compounded alternatives. This has been a uniquely difficult issue in the weight-loss ...

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its annual sales forecast on Wednesday, citing a decline in its US market share.

Novo Nordisk, Eli Lilly Tea Up Next-Gen Drugs. For Novo Nordisk stock, though, it will be important to see how the company builds its pipeline of experimental weight-loss drugs, says Carnegie's Afzal.

Novo Nordisk is trialling its weight-loss drugs to explore if they can reduce alcohol intake and treat alcoholic liver disease, as it seeks to expand the uses of the blockbuster treatments.

Soaring sales of weight loss and diabetes drugs Wegovy and Ozempic have pushed Europe’s largest company Novo Nordisk to raise its full-year revenue and profits guidance.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Danish pharmaceutical giant Novo Nordisk reported more soaring profits on Thursday thanks to the popularity of anti-diabetes and weight-loss drugs Ozempic and Wegovy, which have made it Europe's ...

Novo Nordisk's U.S.-listed shares had been trending lower since September, plunging 18% one day last month after trial results for its weight-loss drug CagriSema disappointed.

Novo Nordisk A/S has a successor waiting in the wings for the generation of weight-loss shots it pioneered: a pill that helps people shed pounds without the drawbacks of an injection.